NCT06187961View on ClinicalTrials.gov

Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2027

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
PROCEDURE

HAIC

administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.

DRUG

Lenvatinib plus cadonilimab

lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Sponsors

Collaborators (1)

Akesobio
All Listed Sponsors
collaborator

Akesobio

INDUSTRY

lead

Tongji Hospital

OTHER

NCT06187961 - Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter